Endothelial progenitor cells (EPCs) are a subset of the total mononuclear cell population
(tMNCs) that possess an enhanced potential for differentiation within the endothelial‐cell …

An important factor to determine the success of stem cell therapy to the heart is the choice of
cell delivery route. This will affect the fate of donor cells and subsequently influence the …

Cardiovascular disease is the leading cause of death and disability in the Western world. In
addition to the advancement of current therapeutic approaches to reduce the associated …

Stem cells hold significant promise for regeneration of tissue defects and disease-modifying
therapies. Although numerous promising stem cell approaches are advancing in clinical …

Aims Stem cell therapy after myocardial infarction (MI) has been studied in models of
permanent coronary occlusion. We studied the effect of intracoronary administration of …

Over the past decade, cell therapy has emerged as a potential new treatment of a variety of
cardiac diseases, including acute myocardial infarction, refractory angina, and chronic heart …

Abstract Endothelial Progenitor Cells (EPC) were first described in 1997 and have since
been the subject of numerous investigative studies exploring the potential of these cells in …

Stem cells exert therapeutic effects against ischemic stroke via transplantation of exogenous
stem cells or stimulation of endogenous stem cells within the neurogenic niches of …

Acquired cardiovascular diseases and complex congenital heart diseases are leading
causes of morbidity and mortality. Cellular therapy and tissue engineering are emerging as …

Although most cardiac cell therapy trials have focused on patients with acute myocardial
infarction, attempts at “regenerating” chronically failing hearts have also been performed …